These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38823336)

  • 1. Assessing the quality of forced vital capacity measurement in patients with systemic sclerosis.
    Uzun GS; Sarı A; Karcıoğlu O; Sancar EN; Unaldı E; Fırlatan B; Bayram GS; Kılıç L; Akdoğan A
    Semin Arthritis Rheum; 2024 Aug; 67():152466. PubMed ID: 38823336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
    Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
    J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease.
    Nawata T; Shirai Y; Suzuki M; Kuwana M
    Rheumatology (Oxford); 2021 Jan; 60(1):250-255. PubMed ID: 32699895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
    Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
    Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis.
    Zhang XJ; Bonner A; Hudson M; ; Baron M; Pope J
    J Rheumatol; 2013 Jun; 40(6):850-8. PubMed ID: 23547215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
    Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
    Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling.
    Man A; Davidyock T; Ferguson LT; Ieong M; Zhang Y; Simms RW
    Rheumatology (Oxford); 2015 Aug; 54(8):1464-71. PubMed ID: 25784774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computer-Aided Tomographic Analysis of Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc). Correlation with Pulmonary Physiologic Tests and Patient-Centred Measures of Perceived Dyspnea and Functional Disability.
    Salaffi F; Carotti M; Di Donato E; Di Carlo M; Ceccarelli L; Giuseppetti G
    PLoS One; 2016; 11(3):e0149240. PubMed ID: 26930658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
    Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
    Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
    Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
    J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
    Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
    Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
    Le Gouellec N; Duhamel A; Perez T; Hachulla AL; Sobanski V; Faivre JB; Morell-Dubois S; Lambert M; Hatron PY; Hachulla E; Béhal H; Matran R; Launay D; Remy-Jardin M
    PLoS One; 2017; 12(8):e0181692. PubMed ID: 28763468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
    Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
    Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Ghazipura M; Macrea M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Feb; 21(2):328-337. PubMed ID: 37773003
    [No Abstract]   [Full Text] [Related]  

  • 15. Ventilation distribution as a contributor to the functional exercise capacity in patients with systemic sclerosis-associated interstitial lung disease without pulmonary hypertension.
    Andrade FM; Oliveira AD; Lopes AJ
    Braz J Med Biol Res; 2019; 52(8):e8513. PubMed ID: 31365695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects.
    Maher TM; Bourdin A; Volkmann ER; Vettori S; Distler JHW; Alves M; Stock C; Distler O
    Respir Res; 2022 Jul; 23(1):178. PubMed ID: 35790961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.
    Roofeh D; Barratt SL; Wells AU; Kawano-Dourado L; Tashkin D; Strand V; Seibold J; Proudman S; Brown KK; Dellaripa PF; Doyle T; Leonard T; Matteson EL; Oddis CV; Solomon JJ; Sparks JA; Vassallo R; Maxwell L; Beaton D; Christensen R; Townsend W; Khanna D
    Semin Arthritis Rheum; 2021 Dec; 51(6):1331-1341. PubMed ID: 34493396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary function in Thai patients with systemic sclerosis; a single center 6-year retrospective study.
    Pirompanich P; Sathitakorn O; Sakulvorakitti T
    F1000Res; 2024; 13():296. PubMed ID: 38835937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study.
    Moor CC; van Leuven SI; Wijsenbeek MS; Vonk MC
    Rheumatology (Oxford); 2021 May; 60(5):2467-2471. PubMed ID: 33212511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.